

AMANTADINE ER

Products Affected

Step 2:

- OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 258 MG TABLET, EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS.
-----------------	--

ANTICONVULSANTS

Products Affected

Step 2:

- APTIOM 200 MG TABLET
- APTIOM 400 MG TABLET
- APTIOM 600 MG TABLET
- APTIOM 800 MG TABLET
- BANZEL 200 MG TABLET
- BANZEL 40 MG/ML ORAL SUSPENSION
- BANZEL 400 MG TABLET
- FYCOMPA 0.5 MG/ML ORAL SUSPENSION
- FYCOMPA 10 MG TABLET
- FYCOMPA 12 MG TABLET
- FYCOMPA 2 MG TABLET
- FYCOMPA 4 MG TABLET
- FYCOMPA 6 MG TABLET
- FYCOMPA 8 MG TABLET
- OXTELLAR XR 150 MG TABLET,EXTENDED RELEASE
- OXTELLAR XR 300 MG TABLET,EXTENDED RELEASE
- OXTELLAR XR 600 MG TABLET,EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR GENERIC ANTICONVULSANT AGENT (CARBAMAZEPINE, DIVALPROEX SODIUM, GABAPENTIN, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, TIAGABINE, TOPIRAMATE, VALPROIC ACID, OR ZONISAMIDE), WITHIN THE PAST 120 DAYS.
-----------------	--

ANTIDEPRESSANTS

Products Affected

Step 2:

- FETZIMA 120 MG
CAPSULE,EXTENDED RELEASE
- FETZIMA 20 MG (2)-40 MG (26)
CAPSULE,EXTENDED RELEASE,24
HR,DOSE PACK
- FETZIMA 20 MG
CAPSULE,EXTENDED RELEASE
- FETZIMA 40 MG
CAPSULE,EXTENDED RELEASE
- FETZIMA 80 MG
CAPSULE,EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR TRINTELLIX AND VIIBRYD WITHIN THE PAST 365 DAYS.
----------	--

ANTIDIABETIC AGENTS - MISCELLANEOUS

Products Affected

Step 2:

- GLYXAMBI 10 MG-5 MG TABLET
- GLYXAMBI 25 MG-5 MG TABLET
- INVOKAMET 150 MG-1,000 MG TABLET
- INVOKAMET 150 MG-500 MG TABLET
- INVOKAMET 50 MG-1,000 MG TABLET
- INVOKAMET 50 MG-500 MG TABLET
- INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKANA 100 MG TABLET
- INVOKANA 300 MG TABLET
- JARDIANCE 10 MG TABLET
- JARDIANCE 25 MG TABLET
- SYNJARDY 12.5 MG-1,000 MG TABLET
- SYNJARDY 12.5 MG-500 MG TABLET
- SYNJARDY 5 MG-1,000 MG TABLET
- SYNJARDY 5 MG-500 MG TABLET
- SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR METFORMIN, METFORMIN ER, A SULFONYLUREA AGENT (GLYBURIDE, GLIPIZIDE, GLIMEPIRIDE), PIOGLITAZONE, OR COMBINATION OF A SULFONYLUREA-METFORMIN WITHIN THE PAST 120 DAYS.
-----------------	---

ANTI-INFLAMMATORY AGENTS - GI

Products Affected

Step 2:

- DIPENTUM 250 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSION OF 1 OF THE FOLLOWING: APRISO, BALSALAZIDE, MESALAMINE 400 MG CAP(DRTAB), MESALAMINE DR 800 MG TAB, OR FORMULARY MESALAMINE 1.2 G DR TAB WITHIN THE PAST 120 DAYS.
----------	--

ANTIPSYCHOTIC AGENTS

Products Affected

Step 2:

- *aripiprazole 10 mg disintegrating tablet*
- *aripiprazole 15 mg disintegrating tablet*
- CAPLYTA 42 MG CAPSULE
- *clozapine 100 mg disintegrating tablet*
- *clozapine 12.5 mg disintegrating tablet*
- *clozapine 150 mg disintegrating tablet*
- *clozapine 200 mg disintegrating tablet*
- *clozapine 25 mg disintegrating tablet*
- FANAPT 1 MG TABLET
- FANAPT 10 MG TABLET
- FANAPT 12 MG TABLET
- FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK
- FANAPT 2 MG TABLET
- FANAPT 4 MG TABLET
- FANAPT 6 MG TABLET
- FANAPT 8 MG TABLET
- SAPHRIS 10 MG SUBLINGUAL TABLET
- SAPHRIS 2.5 MG SUBLINGUAL TABLET
- SAPHRIS 5 MG SUBLINGUAL TABLET
- SECUADO 3.8 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH
- SECUADO 5.7 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH
- SECUADO 7.6 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH
- VERSACLOZ 50 MG/ML ORAL SUSPENSION
- VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK
- VRAYLAR 1.5 MG CAPSULE
- VRAYLAR 3 MG CAPSULE
- VRAYLAR 4.5 MG CAPSULE
- VRAYLAR 6 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSIONS OF ANY TWO ORAL ANTIPSYCHOTICS: RISPERIDONE, CLOZAPINE TABLET, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE WITHIN THE PAST 365 DAYS.
-----------------	--

ANTIPSYCHOTIC AGENTS II

Products Affected

Step 2:

- REXULTI 0.25 MG TABLET
- REXULTI 0.5 MG TABLET
- REXULTI 1 MG TABLET
- REXULTI 2 MG TABLET
- REXULTI 3 MG TABLET
- REXULTI 4 MG TABLET

Details

Criteria	PRIOR CLAIM FOR TWO (2) OF THE FOLLOWING FORMULARY ORAL VERSIONS OF ATYPICAL ANTIPSYCHOTICS (RISPERIDONE, CLOZAPINE, OLANZAPINE, QUETIAPINE, ARIPIPRAZOLE OR ZIPRASIDONE) OR SSRI (CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE OR SERTRALINE) OR SNRI (DESVENLAFAXINE, DULOXETINE OR VENLAFAXINE) WITHIN THE PAST 365 DAYS
-----------------	---

ANTIULCER AGENTS

Products Affected

Step 2:

- *omeprazole 20 mg-sodium bicarbonate 1.1 gram capsule*
- *omeprazole 40 mg-sodium bicarbonate 1.1 gram capsule*

Details

Criteria	PRIOR CLAIM FOR GENERIC FEDERAL LEGEND FORMULARY VERSION OF ORAL LANSOPRAZOLE CAPSULES, OMEPRAZOLE, OR PANTOPRAZOLE WITHIN THE PAST 120 DAYS.
-----------------	---

B VERSUS D ADMINISTRATIVE STEP

Products Affected

Step 2:

- CYCLOPHOSPHAMIDE 25 MG CAPSULE
- CYCLOPHOSPHAMIDE 50 MG CAPSULE
- *methotrexate sodium 2.5 mg tablet*
- XATMEP 2.5 MG/ML ORAL SOLUTION

Details

Criteria	IN ORDER TO ASSIST IN A PART B VS. D PAYMENT DETERMINATION, A PRIOR CLAIM SEEN FOR A RHEUMATOID ARTHRITIS, PSORIASIS OR ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG WITHIN THE PAST 120 DAYS WILL QUALIFY FOR PART D PAYMENT. ALL OTHER INDICATIONS WILL HAVE A PART B VS. D PAYMENT DETERMINATION MADE THROUGH THE FORMULARY EXCEPTION PROCESS PRIOR TO THE APPROVAL OF THE DRUG.
----------	--

DPP-4 INHIBITORS

Products Affected

Step 2:

- JENTADUETO 2.5 MG-1,000 MG TABLET
- JENTADUETO 2.5 MG-500 MG TABLET
- JENTADUETO 2.5 MG-850 MG TABLET
- JENTADUETO XR 2.5 MG-1,000 MG TABLET, EXTENDED RELEASE
- JENTADUETO XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE
- TRADJENTA 5 MG TABLET

Details

Criteria	PRIOR CLAIM FOR JANUMET, JANUMET XR OR JANUVIA WITHIN THE PAST 120 DAYS
----------	---

ELUXADOLINE

Products Affected

Step 2:

- VIBERZI 100 MG TABLET
- VIBERZI 75 MG TABLET

Details

Criteria	PRIOR CLAIM FOR DICYCLOMINE AND XIFAXAN 550MG WITHIN THE PAST 365 DAYS.
-----------------	---

FIDAXOMICIN

Products Affected

Step 2:

- DIFICID 200 MG TABLET

Details

Criteria	PRIOR CLAIM FOR ORAL VANCOMYCIN IN THE PAST 120 DAYS.
-----------------	---

INSULIN/GLP-1 ANALOG

Products Affected

Step 2:

- SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN
- XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN

Details

Criteria	PRIOR CLAIM FOR 2 OF THE FOLLOWING (ONE FROM EACH GROUP): A) LANTUS, LANTUS SOLOSTAR, OZEMPIC, TRESIBA, TRESIBA FLEXTOUCH, TOUJEO MAX SOLOSTAR, TOUJEO SOLOSTAR OR VICTOZA AND B) METFORMIN, METFORMIN ER, SULFONYLUREA AGENT (GLYBURIDE, GLIPIZIDE, GLIMEPIRIDE), COMBO SULFONYLUREA-METFORMIN, OR PIOGLITAZONE IN PAST 365 DAYS.
----------	--

NASAL CORTICOSTEROIDS II

Products Affected

Step 2:

- XHANCE 93 MCG/ACTUATION
BREATH ACTIVATED AEROSOL

Details

Criteria	PRIOR CLAIM FOR A FEDERAL LEGEND FORMULARY VERSION OF MOMETASONE NASAL SPRAY WITHIN THE PAST 120 DAYS
-----------------	---

NOVEL ORAL ANTICOAGULANTS

Products Affected

Step 2:

- PRADAXA 110 MG CAPSULE
- PRADAXA 150 MG CAPSULE
- PRADAXA 75 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR ELIQUIS AND XARELTO IN THE PAST 365 DAYS.
-----------------	---

OPHTHALMIC ALLERGY - NO OTC

Products Affected

Step 2:

- ALREX 0.2 % EYE
DROPS,SUSPENSION

Details

Criteria	PRIOR CLAIM FOR FEDERAL LEGEND LEVOCETIRIZINE , CROMOLYN SODIUM, EPINASTINE, OR FORMULARY OLOPATADINE EYE DROPS WITHIN THE PAST 120 DAYS.
-----------------	---

OPHTHALMIC PROSTAGLANDINS

Products Affected

Step 2:

- ROCKLATAN 0.02 %-0.005 % EYE DROPS

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSION OF LATANOPROST (GENERIC XALATAN OR XALATAN) AND ONE OF THE FOLLOWING: LUMIGAN 0.01%, TRAVATAN Z, ALPHAGAN P 0.1%, COMBIGAN, SIMBRINZA OR AZOPT WITHIN THE PAST 365 DAYS.
-----------------	--

RENIN ANGIOTENSIN SYSTEM INHIBITORS

Products Affected

Step 2:

- TEKTURNA HCT 150 MG-12.5 MG TABLET
- TEKTURNA HCT 150 MG-25 MG TABLET
- TEKTURNA HCT 300 MG-12.5 MG TABLET
- TEKTURNA HCT 300 MG-25 MG TABLET

Details

Criteria	PRIOR CLAIM FOR AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACE INHIBITOR), ACE INHIBITOR COMBINATION, GENERIC ANGIOTENSIN RECEPTOR BLOCKER (ARB), GENERIC ARB COMBINATION OR GENERIC DIRECT RENIN INHIBITORS WITHIN THE PAST 120 DAYS.
-----------------	---

SPRITAM

Products Affected

Step 2:

- SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 250 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 500 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 750 MG TABLET FOR ORAL SUSPENSION

Details

Criteria	PRIOR CLAIM FOR LEVETIRACETAM SOLUTION IN THE PAST 120 DAYS
-----------------	---

TACROLIMUS PACKETS

Products Affected

Step 2:

- PROGRAF 0.2 MG ORAL GRANULES IN PACKET
- PROGRAF 1 MG ORAL GRANULES IN PACKET

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSION OF TACROLIMUS CAPSULES WITHIN THE PAST 120 DAYS
-----------------	---

INDEX

ALREX 0.2 % EYE		FYCOMPA 0.5 MG/ML ORAL	
DROPS,SUSPENSION.....	16	SUSPENSION.....	2
APTIOM 200 MG TABLET.....	2	FYCOMPA 10 MG TABLET.....	2
APTIOM 400 MG TABLET.....	2	FYCOMPA 12 MG TABLET.....	2
APTIOM 600 MG TABLET.....	2	FYCOMPA 2 MG TABLET.....	2
APTIOM 800 MG TABLET.....	2	FYCOMPA 4 MG TABLET.....	2
<i>aripiprazole 10 mg disintegrating tablet.....</i>	<i>6</i>	FYCOMPA 6 MG TABLET.....	2
<i>aripiprazole 15 mg disintegrating tablet.....</i>	<i>6</i>	FYCOMPA 8 MG TABLET.....	2
BANZEL 200 MG TABLET.....	2	GLYXAMBI 10 MG-5 MG TABLET.....	4
BANZEL 40 MG/ML ORAL		GLYXAMBI 25 MG-5 MG TABLET.....	4
SUSPENSION.....	2	INVOKAMET 150 MG-1,000 MG	
BANZEL 400 MG TABLET.....	2	TABLET.....	4
CAPLYTA 42 MG CAPSULE.....	6	INVOKAMET 150 MG-500 MG	
<i>clozapine 100 mg disintegrating tablet.....</i>	<i>6</i>	TABLET.....	4
<i>clozapine 12.5 mg disintegrating tablet.....</i>	<i>6</i>	INVOKAMET 50 MG-1,000 MG	
<i>clozapine 150 mg disintegrating tablet.....</i>	<i>6</i>	TABLET.....	4
<i>clozapine 200 mg disintegrating tablet.....</i>	<i>6</i>	INVOKAMET 50 MG-500 MG	
<i>clozapine 25 mg disintegrating tablet.....</i>	<i>6</i>	TABLET.....	4
CYCLOPHOSPHAMIDE 25 MG		INVOKAMET XR 150 MG-1,000 MG	
CAPSULE.....	9	TABLET, EXTENDED RELEASE.....	4
CYCLOPHOSPHAMIDE 50 MG		INVOKAMET XR 150 MG-500 MG	
CAPSULE.....	9	TABLET, EXTENDED RELEASE.....	4
DIFICID 200 MG TABLET.....	12	INVOKAMET XR 50 MG-1,000 MG	
DIPENTUM 250 MG CAPSULE.....	5	TABLET, EXTENDED RELEASE.....	4
FANAPT 1 MG TABLET.....	6	INVOKAMET XR 50 MG-500 MG	
FANAPT 10 MG TABLET.....	6	TABLET, EXTENDED RELEASE.....	4
FANAPT 12 MG TABLET.....	6	INVOKANA 100 MG TABLET.....	4
FANAPT 1MG(2)-2 MG(2)-4MG(2)-6		INVOKANA 300 MG TABLET.....	4
MG(2) TABLETS IN A DOSE PACK.....	6	JARDIANCE 10 MG TABLET.....	4
FANAPT 2 MG TABLET.....	6	JARDIANCE 25 MG TABLET.....	4
FANAPT 4 MG TABLET.....	6	JENTADUETO 2.5 MG-1,000 MG	
FANAPT 6 MG TABLET.....	6	TABLET.....	10
FANAPT 8 MG TABLET.....	6	JENTADUETO 2.5 MG-500 MG	
FETZIMA 120 MG		TABLET.....	10
CAPSULE,EXTENDED RELEASE.....	3	JENTADUETO 2.5 MG-850 MG	
FETZIMA 20 MG (2)-40 MG (26)		TABLET.....	10
CAPSULE,EXTENDED RELEASE,24		JENTADUETO XR 2.5 MG-1,000 MG	
HR,DOSE PACK.....	3	TABLET, EXTENDED RELEASE.....	10
FETZIMA 20 MG		JENTADUETO XR 5 MG-1,000 MG	
CAPSULE,EXTENDED RELEASE.....	3	TABLET, EXTENDED RELEASE.....	10
FETZIMA 40 MG		<i>methotrexate sodium 2.5 mg tablet.....</i>	<i>9</i>
CAPSULE,EXTENDED RELEASE.....	3	<i>omeprazole 20 mg-sodium bicarbonate 1.1</i>	
FETZIMA 80 MG		<i>gram capsule.....</i>	<i>8</i>
CAPSULE,EXTENDED RELEASE.....	3		

<i>omeprazole 40 mg-sodium bicarbonate 1.1 gram capsule</i>	8	SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION.....	19
OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE.....	1	SPRITAM 250 MG TABLET FOR ORAL SUSPENSION.....	19
OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE.....	1	SPRITAM 500 MG TABLET FOR ORAL SUSPENSION.....	19
OSMOLEX ER 258 MG TABLET, EXTENDED RELEASE.....	1	SPRITAM 750 MG TABLET FOR ORAL SUSPENSION.....	19
OXTELLAR XR 150 MG TABLET,EXTENDED RELEASE.....	2	SYNJARDY 12.5 MG-1,000 MG TABLET.....	4
OXTELLAR XR 300 MG TABLET,EXTENDED RELEASE.....	2	SYNJARDY 12.5 MG-500 MG TABLET.....	4
OXTELLAR XR 600 MG TABLET,EXTENDED RELEASE.....	2	SYNJARDY 5 MG-1,000 MG TABLET.....	4
PRADAXA 110 MG CAPSULE.....	15	SYNJARDY 5 MG-500 MG TABLET....	4
PRADAXA 150 MG CAPSULE.....	15	SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE.....	4
PRADAXA 75 MG CAPSULE.....	15	SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE.....	4
PROGRAF 0.2 MG ORAL GRANULES IN PACKET.....	20	SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE.....	4
PROGRAF 1 MG ORAL GRANULES IN PACKET.....	20	SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE.....	4
REXULTI 0.25 MG TABLET.....	7	TEKTURNA HCT 150 MG-12.5 MG TABLET.....	18
REXULTI 0.5 MG TABLET.....	7	TEKTURNA HCT 150 MG-25 MG TABLET.....	18
REXULTI 1 MG TABLET.....	7	TEKTURNA HCT 300 MG-12.5 MG TABLET.....	18
REXULTI 2 MG TABLET.....	7	TEKTURNA HCT 300 MG-25 MG TABLET.....	18
REXULTI 3 MG TABLET.....	7	TRADJENTA 5 MG TABLET.....	10
REXULTI 4 MG TABLET.....	7	VERSACLOZ 50 MG/ML ORAL SUSPENSION.....	6
ROCKLATAN 0.02 %-0.005 % EYE DROPS.....	17	VIBERZI 100 MG TABLET.....	11
SAPHRIS 10 MG SUBLINGUAL TABLET.....	6	VIBERZI 75 MG TABLET.....	11
SAPHRIS 2.5 MG SUBLINGUAL TABLET.....	6	VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK.....	6
SAPHRIS 5 MG SUBLINGUAL TABLET.....	6	VRAYLAR 1.5 MG CAPSULE.....	6
SECUADO 3.8 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH....	6	VRAYLAR 3 MG CAPSULE.....	6
SECUADO 5.7 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH....	6	VRAYLAR 4.5 MG CAPSULE.....	6
SECUADO 7.6 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH....	6	VRAYLAR 6 MG CAPSULE.....	6
SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN.....	13	XATMEP 2.5 MG/ML ORAL SOLUTION.....	9

XHANCE 93 MCG/ACTUATION BREATH ACTIVATED AEROSOL.....	14
XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN.....	13